Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 68
2001 182
2002 197
2003 209
2004 205
2005 253
2006 307
2007 317
2008 242
2009 293
2010 302
2011 307
2012 396
2013 454
2014 540
2015 696
2016 684
2017 660
2018 655
2019 634
2020 544
2021 545
2022 526
2023 448
2024 513
2025 513
2026 218

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,373 results

Results by year

Filters applied: . Clear all
Page 1
ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025.
Concin N, Matias-Guiu X, Cibula D, Colombo N, Creutzberg CL, Ledermann J, Mirza MR, Vergote I, Abu-Rustum NR, Bosse T, Chargari C, Espenel S, Fagotti A, Fotopoulou C, Gatius S, González-Martin A, Lax S, Levy B, Lorusso D, Macchia G, Marth C, Morice P, Oaknin A, Raspollini MR, Schwameis R, Sehouli J, Sturdza A, Taylor A, Westermann A, Wimberger P, Planchamp F, Nout RA. Concin N, et al. Lancet Oncol. 2025 Aug;26(8):e423-e435. doi: 10.1016/S1470-2045(25)00167-6. Lancet Oncol. 2025. PMID: 40744042
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.
Graham CE, Velasco R, Alarcon Tomas A, Stewart OP, Dachy G, Del Bufalo F, Doglio M, Henter JI, Ortí G, Peric Z, Roddie C, van de Donk NWCJ, Frigault MJ, Ruggeri A, Onida F, Sánchez-Ortega I, Yakoub-Agha I, Penack O. Graham CE, et al. Lancet Oncol. 2025 Apr;26(4):e203-e213. doi: 10.1016/S1470-2045(24)00715-0. Lancet Oncol. 2025. PMID: 40179916 Review.
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial.
Janssen QP, van Dam JL, van Bekkum ML, Bonsing BA, Bos H, Bosscha KP, Bouwense SAW, Brouwer-Hol L, Bruynzeel AME, Busch OR, Coene PLO, van Eijck CHJ, de Groot JWB, Haberkorn BCM, de Hingh IHJT, Karsten TM, Kazemier G, van der Kolk MB, Liem MSL, Loosveld OJL, Luelmo SAC, Luyer MDP, Mekenkamp LJM, Mieog JSD, Nieuwenhuijs VB, Nuyttens JJME, Patijn GA, van Santvoort HC, Stommel MWJ, Versteijne E, de Vos-Geelen J, de Wilde RF, Zonderhuis BM, van der Holt B, Homs MYV, van Tienhoven G, Besselink MG, Wilmink JW, Groot Koerkamp B; Dutch Pancreatic Cancer Group. Janssen QP, et al. Lancet Oncol. 2025 Oct;26(10):1346-1356. doi: 10.1016/S1470-2045(25)00363-8. Epub 2025 Sep 10. Lancet Oncol. 2025. PMID: 40945523 Clinical Trial.
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial.
van den Heerik ASVM, Horeweg N, Haverkort MAD, Kuijsters N, Kommoss S, Koppe FLA, Nowee ME, Westerveld H, De Jong MAA, Frühauf F, Cnossen JS, Mens JWM, Beukema JC, Chargari C, Gillham C, Jurgenliemk-Schulz IM, Vandecasteele K, Hamann M, Kiderlen M, Staebler A, Nijman HW, Wortman BG, Asteinidou E, de Boer SM, van den Hout WB, Verhoeven-Adema KW, Nout RA, Putter H, Bosse T, Creutzberg CL. van den Heerik ASVM, et al. Lancet Oncol. 2026 Jan;27(1):23-35. doi: 10.1016/S1470-2045(25)00612-6. Lancet Oncol. 2026. PMID: 41449145 Clinical Trial.
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study.
Blondeaux E, Sonnenblick A, Agostinetto E, Bas R, Kim HJ, Franzoi MA, Bernstein-Molho R, Linn S, Kwong A, Pogoda K, Balmana J, Smeets A, Bajpai J, Moore HCF, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Mando P, Lee JE, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Guven DC, Lee M, Villarreal-Garza C, Hwang SE, De Marchis L, Puglisi F, Kemp Z, Meireles PA, Parokonnaya A, Werutsky G, Okano M, Azim HA Jr, Mati K, Rosenberg S, Gelber R, Boni L, Lambertini M. Blondeaux E, et al. Lancet Oncol. 2025 Jun;26(6):759-770. doi: 10.1016/S1470-2045(25)00152-4. Epub 2025 May 8. Lancet Oncol. 2025. PMID: 40347973
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study.
Paulson KG, Lau SCM, Ahn MJ, Moskovitz M, Pogorzelski M, Häfliger S, Parkes A, Zhang Y, Hamidi A, Thompson CG, Wermke M. Paulson KG, et al. Lancet Oncol. 2025 Oct;26(10):1300-1311. doi: 10.1016/S1470-2045(25)00480-2. Epub 2025 Sep 8. Lancet Oncol. 2025. PMID: 40934933 Clinical Trial.
Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study.
Li Z, Wang Y, Sun Y, Wang L, Li X, Sun L, He Z, Yang H, Wang Y, Wang Q, Song Z, Hong W, Wang Y, Xia G, Yu Y, Peng M, Song Y, Wang D, Meng R, Fang J, Luo Y, Liang W, Hu S, Wang Z, Song K, Li Y, Yang L, Shi W, Lu S. Li Z, et al. Lancet Oncol. 2025 Apr;26(4):437-446. doi: 10.1016/S1470-2045(25)00012-9. Epub 2025 Feb 25. Lancet Oncol. 2025. PMID: 40020696 Clinical Trial.
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial.
Post CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Leary A, Ottevanger PB, McCormack M, Khaw P, D'Amico R, Fyles A, Chargari C, Kitchener HC, Do V, Lissoni A, Provencher D, Genestie C, Nijman HW, Whitmarsh K, Jürgenliemk-Schulz IM, Feeney A, Lutgens LCHW, Bouma J, Leon-Castillo A, Nout RA, Putter H, Bosse T, Creutzberg CL. Post CCB, et al. Lancet Oncol. 2025 Oct;26(10):1370-1381. doi: 10.1016/S1470-2045(25)00379-1. Epub 2025 Sep 5. Lancet Oncol. 2025. PMID: 40921169 Free PMC article. Clinical Trial.
Truth and accountability.
The Lancet Oncology. The Lancet Oncology. Lancet Oncol. 2025 Sep;26(9):1123. doi: 10.1016/S1470-2045(25)00486-3. Lancet Oncol. 2025. PMID: 40907506 No abstract available.
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis.
Di Federico A, Stumpo S, Mantuano F, De Giglio A, Lo Bianco F, Pecci F, Alessi JV, Wang X, Sperandi F, Melotti B, Gelsomino F, Skoulidis F, Garassino MC, Peters S, Awad MM, Ardizzoni A, Ricciuti B. Di Federico A, et al. Lancet Oncol. 2025 Nov;26(11):1443-1453. doi: 10.1016/S1470-2045(25)00429-2. Epub 2025 Sep 29. Lancet Oncol. 2025. PMID: 41038207
10,373 results
You have reached the last available page of results. Please see the User Guide for more information.